A proof-of-concept double blinded, single-dose, randomized, placebo-controlled, seven day safety and bioavailability study of AQS1301 (once-weekly, transdermal aripiprazole) in healthy volunteers

Trial Profile

A proof-of-concept double blinded, single-dose, randomized, placebo-controlled, seven day safety and bioavailability study of AQS1301 (once-weekly, transdermal aripiprazole) in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Psychotic disorders
  • Focus First in man; Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 03 Apr 2017 Status changed from recruiting to completed, according to an Aequus Pharmaceuticals media release.
    • 14 Feb 2017 According to an Aequus Pharmaceuticals media release, the company expects to report topline results from this multi-dose study in the first quarter of 2017.
    • 14 Feb 2017 According to an Aequus Pharmaceuticals media release, the company has completed the treatment phase of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top